UK NEQAS

Leucocyte Immunophenotyping

www.ukneqasli.co.uk





New Information for 2024 - 2025 EQA/PT Programmes for Molecular Haemato-Oncology

Merging of the JAK2 p.Val617Phe Mutation Status and Myeloproliferative Neoplasms Diagnostic Testing programmes - UK NEQAS LI is consolidating the JAK2 p.Val617Phe (V617F) Mutation Status and the Myeloproliferative Neoplasms Diagnostic Testing programmes for the 2024 - 2025 registration period. Further details will be provided as this development progresses.

Registration by marker for MRD for AML by Molecular Methods - During registration for 2024 - 2025, participants will be asked to specify the markers they test in the Measurable Residual Disease in Acute Myeloid Leukaemia by Molecular Methods programme. Participants will only be shipped the samples they require for testing which will reduce plastic waste. Costing will be tiered based on how many markers participants test.

Diffuse large B cell lymphoma liquid biopsy study - UK NEQAS LI will be running a small pilot study assessing the use of next generation sequencing based liquid biopsy testing in diffuse large B cell lymphoma. If you are interested in taking part in this study, please contact **admin@ukneqasli.co.uk**

The Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia programme is scheduled for accreditation - UK NEQAS LI have submitted the Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia programme to our accrediting body (UKAS) for accreditation and hope for its inclusion in our formal scope of accreditation in 2024 - 2025. This will allow for the implementation of formal performance monitoring.

Update to ISO 17043:2023 - An update to the ISO 17043 standards, to which EQA/PT providers are accredited, was released in May 2023. There are major new sections on impartiality, risk and information management. EQA/PT providers have a three-year transition window to show compliance to the new standards. UK NEQAS LI is currently performing a gap analysis to identify areas where additional work will be required to demonstrate compliance in 2024 - 2025.

SEE WEBSITE FOR FULL INFORMATION ON ALL OF THE ABOVE CHANGES

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI Pegasus House 4th Floor Suite 463a Glossop Road Sheffield \$10 2QD United Kingdom

Tel: +44 (0)114 2673600 Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register.